Why ADC Therapeutics SA’s (ADCT) Stock Is Up 7.04%
As of Friday, July 17, ADC Therapeutics SA’s ADCT share price has surged by 7.04%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound’ and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company’s pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Commentary & Analysis
Why ADC Therapeutics SA’s (ADCT) Stock Is Down 5.64%
As of Friday, July 10, ADC Therapeutics SA’s ADCT share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why ADC Therapeutics SA’s (ADCT) Stock Is Up 7.60%
As of Tuesday, July 07, ADC Therapeutics SA’s ADCT share price has surged by 7.60%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ADC Therapeutics SA’s (ADCT) Stock Is Up 6.91%
As of Thursday, July 02, ADC Therapeutics SA’s ADCT share price has surged by 6.91%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why ADC Therapeutics SA’s (ADCT) Stock Is Up 7.94%
As of Wednesday, July 01, ADC Therapeutics SA’s ADCT share price has surged by 7.94%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ADCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $141.2 | $251.9 | 24% |
|
| Shares Out (Mil) | 127.2 | 50.8 | 68% |
|
| Institutional Ownership | 91.7% | 92.0% | 60% |
|
| Float (Mil) | 100.4 | 40.5 | 61% |
|
| Beta | 1.84 | 0.95 | 90% |
|
| Avg Daily Volume (000s) | 829 | 447 | 67% |
|
| Price Change (52-week) |
(61.6%) | 54.2% | 12% |
|
| Growth | ADCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.0% | na |
|
| Net Income (5yr) | 10.4% | (9.8%) | 55% |
|
| EPS (5yr) | 21.5% | 16.3% | 70 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (56.2%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ADCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $79 | $39 | 24% |
|
| Net Income (TTM) (Mil) | ($137) | ($43) | 9% |
|
| EPS (TTM) | ($1.077) | ($1.600) | 21% |
|
| Operating Cash Flow (TTM) (Mil) | ($115) | ($30) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $36 | $3 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $417 | $5 | 57% |
|
| Enterprise Value (Q1) (Mil) | $608 | $182 | 36% |
|
| Valuation | ADCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.60 | na |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ADCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (26.3%) | 63.8% | 3% |
|
| Net Margin | (173.0%) | (64.7%) | 5% |
|
| ROA | (48.6%) | (49.7%) | 12% |
|
| ROE | 60.3% | (55.4%) | 94% |
|
| Liabilities to Assets | 174.2% | 30.3% | 98% |
|
| F-Score | 4 | 3 | 34% |
|
ADC Therapeutics SA did not pass any screens on 7/30/2026.
